Skip to content
Dosage GuideResearch Reference

Atrial Natriuretic Peptide (ANP) Dosage

Research-based dosing protocols, timing guidance, and reconstitution reference for Atrial Natriuretic Peptide (ANP). All information is for educational purposes only.

Quick Answer

ANP, primarily administered intravenously in research, is typically infused at 0.01-0.05 mcg/kg/min continuously for up to 72 hours in acute settings like heart failure. Subcutaneous injections have limited utility due to ANP's short half-life. Dosage adjustments are crucial to avoid hypotension. No oral formulations are currently available or researched.

→ Atrial Natriuretic Peptide (ANP) Benefits→ Atrial Natriuretic Peptide (ANP) Side Effects→ Full Atrial Natriuretic Peptide (ANP) Profile
Table of Contents

Standard Dosage Range

Research dosing range: 0.01-0.05 mcg/kg/min (IV infusion)

Educational reference only

These dosage ranges are derived from preclinical research and community protocols. No human clinical dose-ranging trials have established therapeutic doses for most research peptides. Always consult a qualified healthcare provider before starting any peptide protocol.

Dosage by Use Case

Acute Decompensated Heart Failure

0.01-0.02 mcg/kg/minContinuous IV infusion
Duration

24-72 hours

Titrate to effect. Monitor blood pressure closely. Carperitide (recombinant ANP) is approved in Japan for this indication. Goal is to reduce pulmonary congestion and improve cardiac output without causing significant hypotension.

Post-Cardiac Surgery Renal Protection

0.01-0.03 mcg/kg/minContinuous IV infusion
Duration

24-48 hours

Initiate immediately post-op. May reduce the incidence of acute kidney injury. Monitor urine output and creatinine levels.

Resistant Hypertension (investigational)

0.02-0.05 mcg/kg/minContinuous IV infusion
Duration

24 hours

For patients unresponsive to conventional antihypertensive medications. Monitor for excessive diuresis and electrolyte imbalances.

Timing & Frequency

Intravenous ANP administration requires continuous infusion due to its rapid degradation. Subcutaneous injections are less practical given the short half-life (~2-5 minutes) unless sustained-release formulations are developed. No specific timing considerations other than continuous delivery.

Cycle Guidance

ANP is not typically used in cycles due to its short half-life and primary use in acute medical settings. Continuous infusion is necessary for sustained effects. Long-term intermittent dosing strategies are not established.

Reconstitution Reference

Quick reference for reconstituting Atrial Natriuretic Peptide (ANP). For custom vial sizes and concentrations, use the Reconstitution Calculator.

Common Vial SizeVaries (typically supplied as a concentrated solution)
BAC Water VolumeNot applicable (supplied as a solution for IV infusion)
Concentration & DrawVaries by product; follow manufacturer instructions for dilution
StorageRefrigerate per manufacturer instructions. Protect from light.
StabilityFollow manufacturer guidelines; typically stable for 24 hours after dilution.
Use the Reconstitution Calculator → for precise injection volumes based on your exact vial size, water volume, and desired dose.

Frequently Asked Questions

What is the typical ANP dosage for acute heart failure?
In clinical studies and practice (especially in Japan with carperitide), ANP is typically infused intravenously at 0.01-0.02 mcg/kg/min continuously for 24-72 hours. Dosage is carefully titrated based on blood pressure and urine output.
Why can't ANP be taken orally?
ANP is a peptide and would be rapidly degraded in the gastrointestinal tract by digestive enzymes. Intravenous administration is required to achieve therapeutic blood levels.
How is ANP administered?
ANP is administered via continuous intravenous infusion using a pump to deliver a precise dose over a sustained period. Subcutaneous administration is limited by its short half-life.
What happens if the ANP infusion rate is too high?
Excessively high ANP infusion rates can cause significant hypotension (low blood pressure) and excessive diuresis, potentially leading to dehydration and electrolyte imbalances. Careful monitoring is essential.
Are there any sustained-release ANP formulations?
Sustained-release formulations of ANP are under development to overcome its short half-life and allow for less frequent administration, but none are currently clinically available.
How is ANP concentration calculated for IV infusion?
ANP is usually supplied as a concentrated solution. The concentration is determined by the manufacturer, and healthcare professionals dilute it further to achieve the desired infusion rate based on the patient's weight.

References

  1. 1
    Carperitide (recombinant ANP) for acute heart failure: clinical evidence from Japanese trials(2008)PubMed ↗
  2. 2
    Low-dose carperitide for protection against acute kidney injury after cardiac surgery(2013)PubMed ↗
  3. 3
    The effects of intravenous carperitide on renal function in patients with acute heart failure(2014)PubMed ↗

Last updated: 2026-02-19